Daily Archives: December 3, 2018

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

LUGANO, Switzerland and San Diego, USA, December 3, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced interim data from a Phase 2 study evaluating pracinostat, a histone deacetylase inhibitor, in combination with azacitadine for the treatment of patients with IPSS-R high/very high-risk of Myelodysplastic Syndrome (MDS). The data demonstrate a 9% discontinuation rate due to adverse events, a substantially lower rate than observed in an earlier study, as well as an encouraging 36% complete response rate among patients receiving at least 6 cycles of treatment. These data are being presented today at the 2018 American Society of Hematology (ASH) Annual Meeting.

The ongoing Phase 2 open-label study is evaluating a 45 mg dose of pracinostat in combination with azacitadine in order to improve safety/tolerability and retain patients in study longer than in an earlier Phase 2 study evaluating a 60 mg dose. Prolonged treatment is envisaged to result in a systemic exposure to pracinostat sufficient to achieve the desired treatment effect. The data reported today reinforce results from a planned May 2018 interim analysis meeting a predefined discontinuation threshold and suggest a reduced dose of pracinostat may allow MDS patients to remain on treatment longer and thereby increase the likelihood of a treatment response. If the current Phase 2 open-label study is successful, Helsinn intends to initiate a global registration study.

Ehab Atallah, M.D., Study Chair, Associate Professor of Medicine, Medical College of Wisconsin, said:Treatment options for patients with a higher risk of MDS are still limited and following diagnosis the survival rate is less than 18 months with the current standard of care. At the time of the Phase 2 data announced this year in May, I was excited to see that this treatment demonstrated that it can be offered to patients as a combination therapy and potentially improve outcomes. We’re pleased that the threshold for expansion of this study has been met, and I look forward to continuing to observe the progress of this combination treatment.”

Ruben Giorgino, M.D. Ph.D. Helsinn Group Head of Clinical Development, commented: “Helsinn bolsters its commitment in developing pracinostat in combination with hypomethylating agents in patients with AML and with high risk MDS. Moving forward to the second stage of this really important Phase 2 clinical trial in MDS patients represents an important next step in our efforts to understand the potential benefit of pracinostat in these patients with poor prognosis and modest response to hypomethylating monotherapy”. 

Richard Ghalie, M.D., Senior Vice President, Clinical Development at MEI Pharma, commented: “The interim data demonstrating a 9% discontinuation rate due to adverse events, a substantially lower rate than observed in the earlier study, as well as an encouraging complete response rate to date of 36% of patients reaching the first disease assessment at 6 months, represents an opportunity to advance a promising new treatment for patients with high/very high-risk disease that currently have limited options.”

The Phase 2 Study

The ongoing Phase 2 study is open-label and is investigating a 45 mg dose of pracinostat in combination with the standard dose of azacitidine in up to 60 patients with high and very high-risk MDS previously untreated with hypomethylating agents. The primary endpoints of the study are 1) safety and tolerability and 2) overall response rate, defined as complete remission (CR), partial remission (PR) and marrow CR. Secondary endpoints include CR rate, overall hematologic improvement (HI) progression-free survival and overall survival, among others.

As of the end of October 2018, 55 patients have completed at least one cycle of therapy. The data demonstrate a 9% discontinuation rate due to adverse events, 4% of which were early discontinuations (within the first 3 treatment cycles). Of note, 15% of patients discontinued because they advanced to Stem Cell Transplantation. The discontinuation rate reported today continues to meet the pre-defined threshold from the planned interim analysis conducted in May 2018 and is consistent with the discontinuation rate for azacitadine administered as a single agent.

In the group patients receiving at least 6 cycles of treatment, the complete response rate is 36%. The median duration on therapy is 4.7 months (range 0.5-13 months).

The 45 mg dose of pracinostat being evaluated in the Phase 2 is better tolerated than the 60mg dose evaluated in a prior Phase 2 study. Treatment in the current Phase 2 study was

generally well-tolerated: adverse events ≥ Grade 3 reported in 20% or more of patients are febrile neutropenia, anemia, neutropenia and thrombocytopenia. It is notable that patients in the current study were diagnosed with higher-risk MDS than in the prior study.

The study was initially designed with two stages: the completed first stage that met the predefined discontinuation rate threshold, and a randomized and placebo-controlled second
stage triggered upon meeting the pre-defined discontinuation threshold in the first stage. Based on the discontinuation rate meeting the pre-defined threshold in a planned interim analysis in May 2018, the study design was amended by substituting stage 2 with an expanded open-label portion to enroll up to 60 patients to obtain data to support the design of a registration study upon successful completion of the Phase 2 study.

About Higher Risk MDS

Higher risk MDS (high and very high risk in the IPSS-R classification) is a serious medical condition, with median survival of less than 18 months. The high and very high-risk groups represent the highest unmet need in MDS, with median survival estimates of only 1.6 years and 0.8 years, respectively.

The only curative therapy is allogeneic stem cell transplantation (SCT), however most patients with MDS are not candidates for SCT given their typically advanced age, comorbidities and lack of a suitable donor. Standard therapy with HMAs in higher risk MDS provides modest responses, though azacitidine has been shown to improve survival when compared to conventional care regimens. Patients who do not respond to HMAs or progress after therapy with HMAs have a very poor outcome, with a median survival of less than one year.

About Pracinostat

Pracinostat is an oral histone deacetylase (“HDAC”) inhibitor that is in a pivotal Phase 3 study in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia (“AML”) who are unfit for intensive chemotherapy. It is also being evaluated in a Phase 2 study in patients with high or very high-risk myelodysplastic syndrome (“MDS”). The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy.
In August 2016, Helsinn and MEI Pharma entered into an exclusive license, development and commercialization agreement for pracinostat in AML and other potential indications.

The agreement provides that Helsinn is primarily responsible for development and commercialization costs for pracinostat in AML and other indications, including MDS. Pracinostat is an investigational agent and is not approved for commercial use in the U.S. and any country worldwide.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. The Company’s portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine for the treatment of patients with high and very high-risk myelodysplastic syndrome (MDS). MEI Pharma’s clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase 1b study in patients with relapsed/refractory CLL or follicular lymphoma, and voruciclib, an oral,
selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-initiated study in combination with bevacizumab for the treatment of HER2-negative breast cancer. Pracinostat, ME-401, ME-344 and voruciclib are

investigational agents and are not approved for use in the U.S. For more information, please visit www.meipharma.com

MEI Pharma and Helsinn Group Forward-Looking Statements

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

For more information:

Helsinn Group
Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo

MEI Pharma

David A. Walsey

VP of IR and Corporate Communications

Tel: 858-369-7104

investor@meipharma.com

Jason I. Spark

Canale Communications for MEI

Tel: 619-849-6005

jason@canalecomm.com

Silver Star Claims Victory Over iRobot with Final U.S. International Trade Commission Determination in 337-TA-1057

SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) — Shenzhen Silver Star Intelligent Technology Co., Ltd (Silver Star), a leading robotics technology solutions provider, claimed victory in its long dispute with iRobot in Investigation No. 337-TA-1057 based on the Final Determination rendered by the U.S. International Trade Commission (ITC) on November 30, 2018.

The initial ITC complaint was filed by iRobot on April 18, 2017, against eight entities, including Silver Star, alleging infringement of certain claims of six U.S. patents. Before the ITC Hearing, iRobot withdrew two asserted patents and another asserted patent was found to be non-infringed based on summary determination. On June 25, 2018, the Honorable Administrative Law Judge Thomas Pender issued an Initial Determination in favor of Silver Star by finding two of the remaining three asserted patents to be invalid, and the third asserted patent to be non-infringed by Silver Star’s redesigned products.

In its Final Determination, the ITC adopted Judge Pender’s Initial Determination and found two of the asserted patents to be invalid and the third asserted patent to be non-infringed by Silver Star’s redesigned products. As a result, Silver Star’s business in the U.S. will not be impacted by this ITC investigation.

“We welcome the final ruling by the ITC confirming our redesigned products do not infringe any of iRobot’s asserted patents, and we have great respect for the US legal system. We will continue to invest in the U.S. market,” said Lirong Ye, chief executive officer of Silver Star.

He continued, “Silver Star remains committed to our development of cutting-edge Artificial Intelligence technologies and will continue to invest at least 10% of our revenues annually into our research and development, fulfilling our all-time vision to serve our customers and communities with the most innovative smart home products of the future.”

As a China-based leading robotics technology solutions provider, Silver Star has grown into one of the largest original design manufacturing companies in the industry worldwide, serving more than 100 brands, including Haier, Midea, Panasonic and Hoover. The Company values and respects intellectual property rights of all companies and currently holds the biggest floor cleaning robotics IP portfolio in China.

Silver Star’s mission is to continue to design and develop its robot solutions, products and services to enable a better living environment.

For more information:

Doreen Lubeck
DJLubeck, LLC
773-415-1331
djlubeck@yahoo.com

PureCircle Plans Sale of New Stevia Products: Protein, Fiber and Antioxidant Ingredients

These, Added to the Company’s Sweetener Lineup, Will Make Each Stevia Leaf ‘Work Harder’

CHICAGO, Dec. 03, 2018 (GLOBE NEWSWIRE) — PureCircle (LSE: PURE), the world’s leading producer and innovator of great-tasting stevia sweeteners, announces that, after extensive R&D, it has identified high content of proteins, soluble fibers and antioxidants in the stevia plant and plans to begin the commercial production and sale of these new stevia ingredients in the second half of 2019.  PureCircle has nearly 400 patents and patents pending covering its proprietary stevia technology.

Ingredients from the stevia leaf by PureCircle

As the world’s largest supplier of high-grade stevia sweeteners and flavors to the global beverage and food industries, PureCircle uses significant amounts of stevia in producing those ingredients.  This new development — the production and sale of protein, fiber and antioxidants from stevia — will enable PureCircle to utilize much more of each stevia leaf.  As such, the company will be able to make each leaf “work harder.”

That will make PureCircle’s stevia use even more efficient, as it will spread the cost of stevia raw material across the newly expanded array of ingredients sold and to be sold by the company: sweeteners, flavors, fibers, antioxidants and protein (see accompanying graphic). That ensures PureCircle will continue to provide ingredients to its customers at price points that are cost effective for them.  In addition, as all of these types of  ingredients are in high demand by global food and beverage companies, PureCircle will now be able to offer them a portfolio of ingredients from the stevia plant.

Commenting on the commercialization of protein, fiber and antioxidants from stevia, PureCircle CEO Maga Malsagov said:

“At PureCircle, we go to sleep at night and wake up in the morning thinking about stevia.  All of our products are from the stevia leaf, and we strive to make each leaf work harder by unlocking everything this marvel of nature has to offer.” He added: “Protein, fiber and antioxidants are in high demand by beverage and food companies, and these additions to our portfolio will enable us to offer our customers those ingredients from the stevia plant. And it further enhances our efficient use of each leaf, so we can provide the best-tasting stevia leaf sweeteners and flavors cost effectively to our customers.”

The technologies to produce the products PureCircle sells are covered by patents, applied for patents and other intellectual property.  PureCircle’s broad and strong global array of patents are the result of its advanced innovation, research and development work with stevia and its investment therein.  As the result of that, PureCircle has been granted more than 130 stevia-related patents.  These patents – plus more than 250 patents pending and other valuable intellectual property — are directed to a wide range of stevia-related products and processes.

PureCircle’s patent coverage and other intellectual property reflect its expertise and innovation with stevia.  That expertise and innovation enables PureCircle to provide unparalleled support to its customers as they develop zero- and low-calorie beverage and food products and other products using stevia.

PureCircle is the leader in a growth business.  Globally, stevia use is growing.  New products launched globally with stevia posted a +27% increase in the first half of 2018 vs the comparable period in 2017, according to Mintel.  Recent PureCircle advances enable us to significantly boost production of high-grade stevia sweeteners – like Reb M and Reb D — which have the most sugar-like taste and are highly sought after by beverage and food companies.  That means we can supply stevia sweeteners in amounts that customers need as they expand use of stevia ingredients.

By way of background, the story of stevia is evolving.  Not long ago, it was viewed as a plant-based, zero-calorie, single-ingredient sweetener which worked well in some beverage and food applications. Today we offer a range of stevia leaf sweetener ingredients, including Reb M, with sugar-like taste and zero calories. Food and beverage companies have an increasing need for just such an ingredient, because consumers, health experts and governments have become increasingly concerned about obesity and diabetes, and consumers have become increasingly health and wellness conscious.  And, now, we are expanding our offerings to include, not just sweeteners and flavors, but also protein, fiber and antioxidant ingredients – all from the stevia plant.

Media may direct inquiries to:

Carolyn Clark, Head of Global Marketing 
Email:  carolyn.clark@purecircle.com  Phone: 1 (630) 517 0812

Jackson Pillow, Media Relations Manager
Email:  jackson.pillow@purecircle.com  Phone: +1 630 256 8394

About PureCircle

  • PureCircle is the only company that combines advanced R&D with full vertical integration from farm to high-quality, great-tasting innovative stevia sweeteners.
  • The Company collaborates with farmers who grow the stevia plants and with food and beverage companies which seek to improve their low- and no-calorie formulations using a sweetener from plants.
  • PureCircle will continue to: lead in research, development and innovation; produce a growing supply of multiple varieties of stevia sweeteners with sugar-like taste, using all necessary and appropriate methods of production; and be a resource and innovation partner for food and beverage companies.
  • PureCircle stevia flavor modifiers work in synergy with sweeteners to improve the taste, mouthfeel and calorie profile, and enhance the cost effectiveness, of beverage and food products.
  • Founded in 2002, PureCircle is continually investing in breakthrough research and development and it has been granted over 100 stevia-related patents with more than 250 applied for patents pending.
  • PureCircle has offices around the world with the global headquarters in Chicago, Illinois.
  • To meet growing demand for stevia sweeteners, PureCircle is rapidly ramping up its supply capability. It completed expansion of its Malaysian stevia extract facility in March 2017, increasing its capacity to rapidly supply the newer and great-tasting specialty stevia sweeteners and helping provide ever-increasing value to its customers.
  • PureCircle’s shares are listed on the main market of the London Stock Exchange.
  • For more information, visit: www.purecircle.com

About stevia

  • Given the growing global concerns about obesity and diabetes, beverage and food companies are working responsibly to reduce sugar and calories in their products, responding to both consumers and health and wellness advocates. Sweeteners from the stevia plant offer sugar-like taste and are becoming an increasingly important tool for these companies.
  • Like sugar, stevia sweeteners are from plants. But unlike sugar, they enable low-calorie and zero-calorie formulations of beverages and foods.
  • Stevia leaf extract is a natural-based, zero calorie, high-intensity sweetener, used by global food and beverage companies as a great-tasting zero-calorie alternative to sugar and artificial sweeteners.
  • Stevia is a naturally sweet plant native to South America; today, it is grown around the world, notably in Kenya, China and the US.
  • The sweet-tasting parts of the stevia leaf are up to 350 times sweeter than sugar: stevia’s high-intensity sweetness means it requires far less water and land than sugar.
  • Research has shown that the molecules of the stevia leaf are present and unchanged in the dried stevia leaf, through the commercial extraction and purification process, and in the final stevia leaf extract product. All major global regulatory organisations, across 65 countries, have approved the use of high-purity stevia leaf extracts in food and beverages.
  • For more information on the science of stevia, please visit https://www.purecirclesteviainstitute.com/

A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/d8b531ac-4984-4d5b-9780-61aded574efc

PureCircle Plans Sale of New Stevia Products: Protein, Fiber and Antioxidant Ingredients

These, Added to the Company’s Sweetener Lineup, Will Make Each Stevia Leaf ‘Work Harder’

CHICAGO, Dec. 03, 2018 (GLOBE NEWSWIRE) — PureCircle (LSE: PURE), the world’s leading producer and innovator of great-tasting stevia sweeteners, announces that, after extensive R&D, it has identified high content of proteins, soluble fibers and antioxidants in the stevia plant and plans to begin the commercial production and sale of these new stevia ingredients in the second half of 2019.  PureCircle has nearly 400 patents and patents pending covering its proprietary stevia technology.

Ingredients from the stevia leaf by PureCircle

As the world’s largest supplier of high-grade stevia sweeteners and flavors to the global beverage and food industries, PureCircle uses significant amounts of stevia in producing those ingredients.  This new development — the production and sale of protein, fiber and antioxidants from stevia — will enable PureCircle to utilize much more of each stevia leaf.  As such, the company will be able to make each leaf “work harder.”

That will make PureCircle’s stevia use even more efficient, as it will spread the cost of stevia raw material across the newly expanded array of ingredients sold and to be sold by the company: sweeteners, flavors, fibers, antioxidants and protein (see accompanying graphic). That ensures PureCircle will continue to provide ingredients to its customers at price points that are cost effective for them.  In addition, as all of these types of  ingredients are in high demand by global food and beverage companies, PureCircle will now be able to offer them a portfolio of ingredients from the stevia plant.

Commenting on the commercialization of protein, fiber and antioxidants from stevia, PureCircle CEO Maga Malsagov said:

“At PureCircle, we go to sleep at night and wake up in the morning thinking about stevia.  All of our products are from the stevia leaf, and we strive to make each leaf work harder by unlocking everything this marvel of nature has to offer.” He added: “Protein, fiber and antioxidants are in high demand by beverage and food companies, and these additions to our portfolio will enable us to offer our customers those ingredients from the stevia plant. And it further enhances our efficient use of each leaf, so we can provide the best-tasting stevia leaf sweeteners and flavors cost effectively to our customers.”

The technologies to produce the products PureCircle sells are covered by patents, applied for patents and other intellectual property.  PureCircle’s broad and strong global array of patents are the result of its advanced innovation, research and development work with stevia and its investment therein.  As the result of that, PureCircle has been granted more than 130 stevia-related patents.  These patents – plus more than 250 patents pending and other valuable intellectual property — are directed to a wide range of stevia-related products and processes.

PureCircle’s patent coverage and other intellectual property reflect its expertise and innovation with stevia.  That expertise and innovation enables PureCircle to provide unparalleled support to its customers as they develop zero- and low-calorie beverage and food products and other products using stevia.

PureCircle is the leader in a growth business.  Globally, stevia use is growing.  New products launched globally with stevia posted a +27% increase in the first half of 2018 vs the comparable period in 2017, according to Mintel.  Recent PureCircle advances enable us to significantly boost production of high-grade stevia sweeteners – like Reb M and Reb D — which have the most sugar-like taste and are highly sought after by beverage and food companies.  That means we can supply stevia sweeteners in amounts that customers need as they expand use of stevia ingredients.

By way of background, the story of stevia is evolving.  Not long ago, it was viewed as a plant-based, zero-calorie, single-ingredient sweetener which worked well in some beverage and food applications. Today we offer a range of stevia leaf sweetener ingredients, including Reb M, with sugar-like taste and zero calories. Food and beverage companies have an increasing need for just such an ingredient, because consumers, health experts and governments have become increasingly concerned about obesity and diabetes, and consumers have become increasingly health and wellness conscious.  And, now, we are expanding our offerings to include, not just sweeteners and flavors, but also protein, fiber and antioxidant ingredients – all from the stevia plant.

Media may direct inquiries to:

Carolyn Clark, Head of Global Marketing 
Email:  carolyn.clark@purecircle.com  Phone: 1 (630) 517 0812

Jackson Pillow, Media Relations Manager
Email:  jackson.pillow@purecircle.com  Phone: +1 630 256 8394

About PureCircle

  • PureCircle is the only company that combines advanced R&D with full vertical integration from farm to high-quality, great-tasting innovative stevia sweeteners.
  • The Company collaborates with farmers who grow the stevia plants and with food and beverage companies which seek to improve their low- and no-calorie formulations using a sweetener from plants.
  • PureCircle will continue to: lead in research, development and innovation; produce a growing supply of multiple varieties of stevia sweeteners with sugar-like taste, using all necessary and appropriate methods of production; and be a resource and innovation partner for food and beverage companies.
  • PureCircle stevia flavor modifiers work in synergy with sweeteners to improve the taste, mouthfeel and calorie profile, and enhance the cost effectiveness, of beverage and food products.
  • Founded in 2002, PureCircle is continually investing in breakthrough research and development and it has been granted over 100 stevia-related patents with more than 250 applied for patents pending.
  • PureCircle has offices around the world with the global headquarters in Chicago, Illinois.
  • To meet growing demand for stevia sweeteners, PureCircle is rapidly ramping up its supply capability. It completed expansion of its Malaysian stevia extract facility in March 2017, increasing its capacity to rapidly supply the newer and great-tasting specialty stevia sweeteners and helping provide ever-increasing value to its customers.
  • PureCircle’s shares are listed on the main market of the London Stock Exchange.
  • For more information, visit: www.purecircle.com

About stevia

  • Given the growing global concerns about obesity and diabetes, beverage and food companies are working responsibly to reduce sugar and calories in their products, responding to both consumers and health and wellness advocates. Sweeteners from the stevia plant offer sugar-like taste and are becoming an increasingly important tool for these companies.
  • Like sugar, stevia sweeteners are from plants. But unlike sugar, they enable low-calorie and zero-calorie formulations of beverages and foods.
  • Stevia leaf extract is a natural-based, zero calorie, high-intensity sweetener, used by global food and beverage companies as a great-tasting zero-calorie alternative to sugar and artificial sweeteners.
  • Stevia is a naturally sweet plant native to South America; today, it is grown around the world, notably in Kenya, China and the US.
  • The sweet-tasting parts of the stevia leaf are up to 350 times sweeter than sugar: stevia’s high-intensity sweetness means it requires far less water and land than sugar.
  • Research has shown that the molecules of the stevia leaf are present and unchanged in the dried stevia leaf, through the commercial extraction and purification process, and in the final stevia leaf extract product. All major global regulatory organisations, across 65 countries, have approved the use of high-purity stevia leaf extracts in food and beverages.
  • For more information on the science of stevia, please visit https://www.purecirclesteviainstitute.com/

A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/d8b531ac-4984-4d5b-9780-61aded574efc